贝伐珠单抗联合XELOX化疗方案治疗晚期结肠癌患者的效果

Effects of Bevacizumab combined with XELOX chemotherapy regimen in treatment of patients with advanced colon cancer

目的:观察贝伐珠单抗联合XELOX化疗方案治疗晚期结肠癌患者的效果。方法:选取2017年6月至2018年8月该院收治的90例晚期结肠癌患者进行前瞻性研究,按照随机数字表法分为对照组和观察组各45例。对照组行XELOX化疗方案治疗,观察组在对照组基础上联合贝伐珠单抗治疗。比较两组临床疗效、T细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+))水平、胃肠不良反应发生率和1、3年生存率。结果:观察组客观缓解率为51.11%(23/45),明显高于对照组的28.89%(13/45),差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)水平均高于治疗前,且观察组高于对照组,两组CD8^(+)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组胃肠不良反应发生率为24.44%(11/45),对照组胃肠不良反应发生率为28.89%(13/45),两组胃肠不良反应发生率比较,差异无统计学意义(P>0.05);观察组1年生存率为97.78%(44/45),对照组1年生存率为93.33%(42/45),两组1年生存成率比较,差异无统计学意义(P>0.05);观察组三年生存率为93.18%(41/44),高于对照组的76.19%(34/42),差异有统计学意义(P<0.05)。结论:贝伐珠单抗联合XELOX化疗方案治疗晚期结肠癌患者可提高客观缓解率和3年生存率,改善T细胞亚群指标水平,优于单纯XELOX化疗方案治疗效果。

Objective: To observe effects of Bevacizumab combined with XELOX chemotherapy regimen in treatment of patients with advanced colon cancer. Methods: A prospective study was conducted on 90 patients with advanced colon cancer admitted to the hospital from June 2017 to August 2018. They were divided into control group and observation group according to the random number table method, 45 cases in each.The control group was treated with XELOX chemotherapy regimen, while the observation group was treated with Bevacizumab on the basis of that of the control group. The clinical efficacy, the levels of T cell subsets(CD3^(+), CD4^(+), CD8^(+)), the incidence of gastrointestinal adverse reactions, and the 1 and 3 years survival rate were compared between the two groups. Results: The total effective rate of the observation group was 51.11%, which was significantly higher than 28.89% of the control group, and the difference was statistically significant(P<0.05). After the treatment, the levels of CD3^(+) and CD4^(+) in the two groups were higher than those before the treatment, and those in the observation group were higher than the control group;the levels of CD8^(+) in the two groups were lower than those before the treatment, and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05). The incidence of gastrointestinal adverse reactions was 24.44% in the observation group and 28.89% in the control group, and the difference was not statistically significant(P>0.05). The 1-year survival rate was 97.78%(44/45) in the observation group and 93.33%(42/45) in the control group, and the difference was not statistically significant(P>0.05). Further, the 3-year survival rate of the observation group was 93.18%(41/44), which was higher than 76.19%(34/42) of the control group, and the difference was statistically significant(P<0.05). Conclusions: Bevacizumab combined with XELOX chemotherapy regimen can improve the total effective rate and the 3-year survival rate of the patients with advanced colon cancer, and improve the levels of T cell subsets. Moreover, it is superior to single XELOX chemotherapy regimen.